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Abstract
Background: Genomic alterations are common features of cancer cells, and some of these changes are proven to
be neoplastic-specific. Such alterations may serve as valuable tools for diagnosis and classification of tumors,
prediction of clinical outcome, disease monitoring, and choice of therapy as well as for providing clues to the
location of crucial cancer-related genes.
Endometrial carcinoma (EC) is the most frequently diagnosed malignancy of the female genital tract, ranking fourth
among all invasive tumors affecting women. Cytogenetic studies of human ECs have not produced very conclusive
data, since many of these studies are based on karyotyping of limited number of cases and no really specific
karyotypic changes have yet been identified. As the majority of the genes are conserved among mammals, the use
of inbred animal model systems may serve as a tool for identification of underlying genes and pathways involved
in tumorigenesis in humans. In the present work we used spectral karyotyping (SKY) to identify cancer-related
aberrations in a well-characterized experimental model for spontaneous endometrial carcinoma in the BDII rat
tumor model.
Results: Analysis of 21 experimental ECs revealed specific nonrandom numerical and structural chromosomal
changes. The most recurrent numerical alterations were gains in rat chromosome 4 (RNO4) and losses in RNO15.
The most commonly structural changes were mainly in form of chromosomal translocations and were detected in
RNO3, RNO6, RNO10, RNO11, RNO12, and RNO20. Unbalanced chromosomal translocations involving RNO3p was
the most commonly observed structural changes in this material followed by RNO11p and RNO10 translocations.
Conclusion: The non-random nature of these events, as documented by their high frequencies of incidence, is
suggesting for dynamic selection of these changes during experimental EC tumorigenesis and therefore for their
potential contribution into development of this malignancy. Comparative molecular analysis of the identified
genetic changes in this tumor model with those reported in the human ECs may provide new insights into
underlying genetic changes involved in EC development and tumorigenesis.
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Introduction
The most frequently diagnosed malignancy of the female
genital tract is cancer of the endometrium. Endometrial
carcinoma (EC) is the predominant sub type, ranking
fourth among all invasive tumors that affect women.
Approximately 85% of the patients diagnosed with this
malignancy are over 50 years of age [1].
As most other cancer types, EC is a complex genetic
disease as its development is influenced by multiple
genetic alterations [2-5]. Cytogenetic studies of ECs
have shown that most tumors have hyperdiploid karyo-
types with relatively minor chromosomal aberrations [6].
The reported cytogenetic data are not conclusive, since
they are based on the karyotyping of limited number of
cases [6], and no really specific karyotypic changes have
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any medium, provided the original work is properly cited.yet been detected. In general, genetic studies of complex
diseases in human is proven to be difficult due to het-
erogeneity of the human population with respect to
genetic background and diversity of the influencing
environmental factors [7-9]. As the majority of the
genes are conserved among mammals, the use of inbred
animal model systems may serve as a powerful tool for
identification of underlying genes and pathways in
human disease phenotypes. There are many animal
models available for studies of human disorders, among
which a number of inbred rat model strains provide
unique models for the analysis of cancer [10,11]. Of
these, four develop EC spontaneously, of which females
f r o mt h eB D I I / H a ns t r a i n( h e r e a f t e rB D I I )i sp r o n et o
develop tumors with the highest incidence (more than
90% among the virgin females) [12,13]. EC development
in BDII rats has similarities in pathogenesis, histopatho-
logical and molecular properties to human EC, and thus
the inbred BDII strain represents a unique model for
analysis of EC tumorigenesis [14]. This tumor model
has been genetically well characterized [3,4,15,16], but
there still is much important genetic information to be
fully understood [13].
Genomic alterations are common features of cancerous
cells, which may appear as chromosomal aberrations,
including numerical and structural changes [17]. In cyto-
genetic studies of neoplasms it is shown that a large frac-
tion of chromosomal abnormalities in many cancer types
are neoplastic-specific. Such findings might thus serve as
valuable tools for diagnosis and classification of tumors,
prediction of clinical outcome, disease monitoring, and
the choice of therapy [18]. They additionally may provide
clues to locations of crucial cancer-related genes involved
in tumorigenesis and tumor progression pathways.
Detailed analysis of these genes may offer valuable tools
f o re a r l yd i a g n o s i sa n dp r o g n o s i so fc a n c e ra sw e l la sf o r
the drug discovery. In this regard, genomic approaches
have proven to be effective in detecting chromosomal
alterations pinpointing candidate genes that are involved
in cancer development [17].
Spectral karyotyping (SKY) is a method used to detect
aberrations and rearrangements through direct examina-
tion of metaphases and chromosomes. In SKY analysis,
the chromosomes are labeled with their specific different
dyes and thus different forms of chromosomal altera-
tions are easily detected [19]. The SKY technique is very
useful in clinical cytogenetics, in particular in the analy-
sis of tumor cells, where multiple and complex chromo-
some aberrations are common [20,21].
Here, we report results from detailed cytogenetic analy-
sis of a set of 21 BDII rat endometrial adenocarcinoma
primary cell cultures using SKY technique. We found spe-
cific nonrandom chromosomal changes in his model with
potential contribution to endometrial carcinogenesis.
Materials and methods
Tumor material
EC Susceptible BDII females (with incidence of more than
90%) were crossed to EC resistant SPRD-Cu3/Han and
BN/Han males (hereafter SPRD and BN, with incidences
of less than 10%). F1 progenies were backcrossed to the
female rats of the susceptible parental strains (BDII) to
produce backcrosses (N1), or intercrossed in brother-sister
mating to produce F2 progeny. Spontaneously arising
tumors developed in a proportion of F1, F2 and N1 pro-
geny. All tumors were characterized histopathologically
and the majority were classified as EC. The RUT (Rat
Uterine Tumors) specimens represent ECs developed in
the F1 and F2 progenies and NUT (N1 Uterine Tumor)
specimens represent ECs developed in the backcross (N1)
progeny. Small pieces of fresh tumor tissue were used to
set up primary cell cultures [22]. Twenty-one of these pri-
mary tumor cell cultures were used in the present study
(Table 1), 10 derived from crosses with the SPRD back-
ground and 11 with the BN background. A rat embryo
fibroblasts (REF) cell culture was used as normal control
[23]. All animal experiments was approved by the local
ethical committee (Institute of Laboratory Animal Science
and Central Animal Facility, Hannover Medical School,
Germany).
Chromosome preparations
Cells were treated with Colcemid (0.05 ug/ml, Life Tech-
nologies, Grand Island, NY), harvested after 20 min by
mitotic shake-off and pelletized by centrifugation. The pel-
l e tw a sr e - s u s p e n d e di n0 . 0 7 5MK C la n dl e f ta tr o o m
temperature for 15 min. Subsequently, fixation was carried
out with methanol-acetic acid fixative series [24]. The
chromosome spreads were air-dried and stored at room
temperature for 5-6 days prior to the SKY experiments.
Hybridization
Slides were pretreated with pepsin to minimize the non-
specific binding and to reduce background fluorescence.
T h es l i d e sw e r et h e nw a s h e di naP B Sa n dM g C l 2 solu-
tion to stop the pepsin digestion and incubated in a solu-
tion of 1% formaldehyde in 1 × PBS/MgCl2 for 10
minutes to strengthen the chromosomal structure. The
rat SKY probe (Applied Spectral Imaging, Israel, ASI)
was denatured at 80°C for 7 minutes and then incubated
at 37°C for 60 minutes. Metaphase slides were denatured
in 70% formamide at 75°C for 2-3 minutes, 5 μlo ft h e
denatured probe was added to the denatured metaphase
chromosomes and the hybridization was carried out for
48 hr at 37°C in a humidity chamber.
Detection and image analysis
Following the hybridization step, excess of the probe
was washed from the slides. The hybridized probes were
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staining followed by a Cy5.5 sheep anti mouse antibody
treatment. The chromosomes were counterstained with
4,6-diamino-2-phenylindole (DAPI) in an anti-fade solu-
tion (ASI). Imaging of the signals was carried out using
the SpectraCube system mounted on a Zeiss Axioskop 2
Mot Plus Imaging microscope. The images were ana-
lyzed using the HiSKY
®multispecies software (ASI).
Results
In average 24 metaphases per tumor samples were ana-
lyzed, except for two tumors for which only 6 (NUT 42)
and 14 (NUT98) analyzable metaphases were available
(Table 1). The REF cell line displayed a normal diploid
karyotype in all of the 25 metaphases analyzed. All tumor
samples, but two (RUT2 and NUT84), showed a mixed
population of clones with different ploidy grades (Table 1).
The majority of tumors displayed a complex pattern of
numerical and structural aberrations (Figure 1). Using the
International System for Human Cytogenetic Nomencla-
ture (ISCN 1995) and literature on nomenclature for G-
bands in rat chromosome [25,26], we determined the
most common cytogenetic changers among the tumors
(Table 2).
Discussion
Chromosomal instability (CIN) is a common feature of
most human cancers. CIN may result in imbalances in
the chromosome numbers (aneuploidy) and/or
enhanced rate of structural aberrations (translocation,
inversion, deletion, insertion, etc). These changes may
be important mechanisms of activating or inactivating of
oncogenes and tumor suppressor genes, respectively. A
crucial question of cancer etiology is then whether CIN
is an early event and thus a driving force of tumorigen-
esis [27]. In general, detailed analysis of CIN in tumor
cells is hampered by limitations in conventional banding
techniques as well as by the complex nature of cancer-
related chromosome aberrations in tumor cells. SKY is a
molecular cytogenetic techn i q u eb yw h i c hm a n yf o r m s
of multiple and complex aberrations can easily be char-
acterized. SKY has made it possible to detect the so-
called hidden structural alterations, such as transloca-
tions in regions with similar banding patterns that could
have been left otherwise undetected by the classical
cytogenetic methods. In cancer cells, next after numeri-
cal chromosomal changes and translocations, formation
of unidentifiable marker chromosomes of multiple chro-
mosomal origins is common [28]. Identification of
Table 1 Twenty-one primary tumors cell lines derived from ECs in F1, F2 and N1 progeny after crosses between EC
susceptible BDII females and EC non-susceptible SPRD and BN males
Tumor Background
(cross)
Ploidy level Total metaphases analyzed
Diploidy Triploidy Tetraploidy Others
NUT3 SPRD (N1) 16 2 5 23
NUT7 SPRD (N1) 6 4 13 1 24
NUT12 SPRD (N1) 2 22 1 25
NUT29 SPRD (N1) 14 4 3 21
NUT39 SPRD (N1) 10 9 1 20
NUT42 SPRD (N1) 4 0 1 1 6
NUT47 SPRD (N1) 19 3 2 24
NUT84 SPRD (N1) 26 26
RUT2 SPRD (F1) 26 26
RUT6 SPRD (F2) 1 28 29
RUT13 SPRD (F2) 6 18 24
NUT6 BN (N1) 5 18 23
NUT50 BN (N1) 6 23 2 31
NUT52 BN (N1) 9 7 7 23
NUT97 BN (N1) 10 15 25
NUT98 BN (N1) 14 14
NUT100 BN (N1) 7 17 24
NUT127 BN (N1) 3 9 11 23
NUT128 BN (N1) 3 23 26
RUT7 BN (F1) 23 1 2 26
RUT25 BN (F2) 13 11 3 27
Background: genetic background of the animals that developed tumors (cross of BDII females to SPRD or BN males); Progeny: F1 - first generation intercross
offspring; F2 - second generation intercross offspring; N1 - first back-cross generation offspring; Ploidy level: number of methaphases that showed diploid,
triploid, tetraploid or other (near haploid, pentaploid and hexaploid) karyotype.
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by using SKY.
Cytogenetic analyses of human ECs have shown these
tumors to mostly exhibit simple karyotypic abnormalities
with few numerical and/or structural chromosomal
rearrangements [29-31]. Despite this relative karyotypic
simplicity, chromosomal aberrations with potential contri-
bution to EC development have only been partially
studied. In the present work, we used a powerful experi-
mental model for spontaneous endometrial carcinogenesis
Figure 1 Examples of depicted SKY analysis results for tumor samples: A) NUT3, B) NUT128. a.R G Bi m a g e ,b. pseudo-colored image, c.
inverted DAPI image (G-band), d. Complete SKY compared to G-banded karyotype.
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EC. Twenty-one rat EC primary tumor cell cultures
derived from solid tumors developed in the female pro-
geny from crosses between EC susceptible BDII female
rats and EC non-susceptible BN and SPRD male rats were
subjected to detailed cytogenetic analysis using SKY. The
majority of tumors displayed a complex pattern of numeri-
cal and structural aberrations (Table 2, Figure 1). To
examine whether certain chromosomes were more fre-
quently involved in aberrations as well as to identify the
most recurrent changes, we calculated the total number of
numerical and structural aberrations per chromosome in
the tumor material (Tables 3 and 4).
To identify non-random numerical chromosome aber-
rations, we calculated the expected and observed num-
bers of chromosomes in all metaphases analyzed in the
tumor panel. In the 490 metaphases analyzed in 21
tumor samples, when the ploidy status of metaphases is
taken into consideration (Table 1), 1311 of each of the 21
chromosomes would be expected if no chromosome gain
or loss would have happened. We next counted the
actual number of chromosomes present in the tumor
material (observed number of chromosomes, Table 3).
Percentage of numerical chromosome changes was
subsequently calculated for each single chromosome. It
appeared chromosome gains were less common (in 9
chromosomes), but more profound (up to 23,34%) com-
pared to chromosome losses (in 11 chromosomes, but up
to 14,19%, Table 3 and Figure 2). The most commonly
gained chromosome in the material was RNO4 (with the
frequency of 23.34%, Figure 2) and the most commonly
lost chromosome was RNO15 (with the frequency of
14.19%, Figure 2).
Amplification of the proximal region of RNO4 has pre-
viously been reported as the most common aberration in
BDII rat EC tumors by comparative genome hybridiza-
tion (CGH) [3,22]. Walentinsson et al.[ 3 2 ]f u r t h e r
reported the genes Cdk6 (cyclin-dependent kinase 6) and
Met (hepatocyte growth factor receptor) as the main tar-
gets for the observed gene amplifications and thus sug-
gested that up-regulation of Cdk6 and/or Met may
contribute to the development of endometrial cancers in
the BDII rat model. Whether the biological significance
of the observed RNO4 gains in the present work is com-
parable to the earlier reported gene amplifications in this
chromosome remains to be investigated.
In earlier studies, losses in the short arm of RNO15
were reported as one of the most characteristic change
Table 2 The most commonly structural aberrations in the tumors (identified in 75% or more of the metaphases
analyzed)
Tumor Range of chr. no. (% of metaphases in
each group)
No. of
metaphases
Recurrent chromosomal changes
NUT3 38-51 (70%), 61-66 (8%), 82-87 (22%) 23 t(2;9;15), t(6;10), t(8;9), der(X)
NUT6 40-51 (22%), 58-71 (78%) 23 t(1;20), der(1), der(2), t(3;6;9), t(9;6;3;6;9), t(9;11), der(10), t(7;12), t(12;17)
NUT7 39-45 (25%), 56-73 (17%), 74-90 (54%), 138
(4%)
24 t(1;X;5;4), t(5;14), t(10;12), t(5;15), t(X;10)
NUT12 38-45 (8%), 56-64 (88%) 114 (4%) 25 t(1;3), t(1;9), t(3;4), t(4;12), t(X;6), t(8;11), der(9), t(10;15), t(11;18), t(18;19)
NUT29 38-49 (67%), 68-73 (19%), 80-86 (14%) 21 t(9;10), many other different translocations
NUT39 57-73 (50%), 74-81 (45%), 141 (5%) 20 t(3;8), t(3;5), HSR on chr. 4, t(6;12), der(7), t(12;17),
NUT42 26 (17%), 37-43 (67%), 79 (17%) 6 numerical aberrations only
NUT47 40-52 (79%), 53 (13%), 90-93 (8%) 24 der(X), numerical aberrations only
NUT50 21-30 (6%), 35-45 (19%), 55-68 (74%) 31 t(3;8), t(9:10), t(3;10), t(8;17), der(X)
NUT52 40-45 (39%), 55-70 (30%), 74-80 (30%) 23 t(1;12), t(6;12), HSR on chr. 6, t(8;8), t(10;20), t(10;16)
NUT84 37-50 (100%) 26 t(2;6), t(2;6;3), t(2;6), t(5;6), t(6;16), t(5;8), der(10)
NUT97 48-52 (40%), 56-63 (60%) 25 del(3), t(3;6), t(7;18), t(2;9)
NUT98 35-49 (100%) 14 t(2;9), der(3), t(3;6), der(18), der(X)
NUT100 36-50 (29%), 61-66 (71%) 24 t(1;13/14), t(2;3), t(3;7;4), t(4;18), der(5), t(6;17), der(9), t(5;10), der(10), t
(11;18)
NUT127 46-48 (13%), 60-73 (39%), 74-78 (48%) 23 t(5;13), t(8;10), t(1;20)
NUT128 40-52 (13%), 53-72 (88%) 26 der(2), der(6), t(2;9), t(X;9;10), t(6;X;9), t(12;13/14), t(16;17), t(5;19), t(12;19), t
(18;19), t(19;20)
RUT2 34-52 (100%) 26 t(3;17), t(5;17), t(6;15), t(10;18), t(10;16), t(5;17)
RUT6 47 (3%), 54-71 (97%), 29 t(2;12), t(3;4), t(6;20), t(7;15), der(10), t(1;16), t(15;20)
RUT7 22-27 (8%), 32-45 (88%), 88 (4%) 26 t(3;8), t(5;1;4), der(4), t(1;5), t(2;8), der(10), 17-not present
RUT13 39-52 (25%), 53-62 (75%) 24 t(3;4;15), t(3;4), t(1;4), t(4;11), t(6;11), t(6;12), t(10;13/14), t(10;15), t(X;18)
RUT25 41-52 (48%), 53-68 (41%), 79-87 (11%) 27 t(3;11), t(1;10), t(17;19), der(X)
t: translocation; der: derivative; HSR: homogenously staining regions.
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homologous to segments of human chromosomes 10q,
6p, 3p, 14q, 8p, and 13q, some of which are reported to
exhibit loss of heterozygosity and deletions in human
endometrial cancers [33-35] and in other human cancer
types [36]. There are a number of important cancer-
related genes located on this chromosome, including
Anxa7 (annexin 7, its human counterpart ANXA7 located
on HSA10q21), which is a tumor suppressor gene asso-
ciated with prostate cancer [37] and Bmp4, Lgals3 and
Cdkn3, whose human counterparts are located on chro-
mosome band 14q22 in human. BMP4 (bone morpholo-
gic protein 4) was shown to be associated with poorly
differentiated gastric cancer and in bone and soft tissue
sarcoma [38,39]. Association of LGALS3 (lectin, galacto-
side-binding soluble 3) is reported with endometrial,
breast and colorectal cancer [40-42], and CDKN3 (cyclin-
dependent kinase inhibitor 3) is known to be involved in
hepatocarcinogenesis and breast and prostate cancer
development [43,44].
We next investigated frequency of non-random struc-
tural chromosomal changes in this material. To address
this, we recorded structural aberrations (amplification,
deletion and translocation) for all of the chromosomes,
metaphases and tumor samples (Table 4). Using the
Pearsson coefficient of correlation test, we examined
whether the total number of observed structural changes
Table 3 Analysis of numerical chromosome changes in 21
experimental EC tumors
Chromosome Observed Obs./Exp. % of gain (+) or loss (-)
1 1317 1.005 +0.46
2 1347 1.027 +2.75
3 1331 1.015 +1.53
4 1617 1.233 +23.34
5 1173 0.895 -10.53
6 1478 1.127 +12.74
7 1253 0.956 -4.42
8 1246 0.950 -4.96
9 1344 1.025 +2.52
10 1260 0.961 -3.89
11 1180 0.900 -9.99
12 1483 1.131 +13.12
13 1142 0.871 -12.89
14 1207 0.921 -7.93
15 1125 0.858 -14.19
16 1491 1.137 +13.73
17 1296 0.989 -1.14
18 1156 0.882 -11.82
19 1427 1.088 +8.85
20 1164 0.888 -11.21
X 1307 0.997 -0.31
The expected number of each chromosome in the tumor panel was
calculated as 1311. The most recurrently gained and lost chromosomes are
marked in gray and black, respectively.
Table 4 Numerical and structural aberrations detected in each chromosome in the tumor panel
Chr. Size (Mb) No. of chromosome Structural changes
Deletion Translocation Amplification Total
1 267.9 1317 55 132 187
2 258.2 1347 33 184 9 226
3 171.1 1331 49 438 487
4 187.1 1617 94 265 30 389
5 173.1 1173 82 242 12 336
6 147.6 1478 68 426 45 539
7 143 1253 73 49 5 127
8 129 1246 19 188 3 210
9 113.4 1344 56 112 1 169
10 110.7 1260 192 219 1 412
11 87.8 1180 24 191 16 231
12 46.8 1483 13 179 5 197
13 111.2 1142 2 44 46
14 112.2 1207 11 41 52
15 109.8 1125 3 155 1 159
16 90.2 1491 15 116 3 134
17 97.3 1296 8 168 6 182
18 87.3 1156 17 117 4 138
19 59.2 1427 10 77 1 88
20 55.3 1164 1 145 3 149
X 160.7 1307 116 82 39 237
“Amplification” represents both the observed HSR and double minutes in metaphases.
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the genome. The analysis revealed that no such correla-
tion existed (rsTOT = 0,351, df = 19, P > 0,05), indicating
that the observed alterations could not be explained by
random events in the genome. Repeating the analysis,
this time for the individual chromosomes, we found that
the observed lack of correlation was mainly due to non-
random aberrations in six chromosomes: RNO3, RNO6,
RNO10, RNO11, RNO12, and RNO20. For these chro-
mosomes, frequencies of observed changes per chromo-
some were higher than could be explained by random
events corresponding to the genomic content of each of
the chromosomes. In five of these chromosomes
(RNO3, RNO6, RNO11, RNO12 and RNO20) over 80%
of the changes were in form of translocations, whereas
deletions and translocations were equally prevalent in
the sixth, i.e.RNO10.
Chromosomal translocations in tumor material can be
classified in two major groups: the tumor-specific trans-
locations, i.e. those that occur at specific cytogenetic
band in a particular chromosome in several tumor sam-
ples and types. The second group is those that occur ran-
domly at different positions of the chromosomes. SKY
analysis of 21 BDII rat ECs showed that both groups of
translocations were present in the tumor panel (Table 2).
Unbalanced chromosomal translocations involving
RNO3 were the most commonly observed structural
changes in the tumor material. RNO3 translocations
seemed to be non-random, since in the majority of cases
(8 out of 14, 57%) the breakpoint was in the short arm of
RNO3, often at the cytogenetic band RNO3p11 (Figure
3), which harbors ribosomal genes. Recurrent unbalanced
translocations of short arm of RNO3 have earlier been
reported and discussed in transformed rat mammary
epithelial cell lines [45]. Furthermore, loss of RNO3p has
been reported in a number of transformed rat cell lines
and in vivo hepatic lesions [46,47] and are suggested to
be involved in mitotic spindle malfunction and thus
aneuploidy in these models [48]. Taken together, these
data suggest RNO3p may contain one or several genes
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Figure 2 Numerical chromosome changes in 21 experimental EC tumors as identified by SKY analysis. As shown, chromosomal gains are
less common, but more profound compared to chromosomal losses.
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region has repeatedly reported in a number of tumor
models, including the model presented in this report, in
mammary tumors as well as in other rat malignancies of
epithelial origin [45-47]. RNO3p is homologous to seg-
ments of human chromosome bands 2q13 and 2q22 as
well as to a larger segment of human chromosome 9,
including cytogenetic bands 9q33-q34.
The second most commonly observed chromosomal
translocations was in RNO11 (in 11 tumors, 52%). In
the majority of cases RNO11 breakpoints were detected
in the short arm of the chromosome, where, similar to
RNO3p, harbors ribosomal genes.
RNO10 was an interesting chromosome in this analy-
sis, since translocation and/or partial deletion of the dis-
tal part of the chromosome was observed in 17 tumors
(71%). Nine tumors (NUT6, NUT7, NUT84, NUT100,
NUT127, RUT2, RUT6, RUT7 and RUT25) showed only
deletion, four (NUT7, NUT127, RUT2 and RUT25) both
deletion and translocation and three (NUT3, NUT97
and NUT128) displayed only translocation in distal
RNO10. Since deletions of distal part of RNO10 were
detected in more than half of the tumors, we propose
that the most direct outcome of RNO10 translocations
might be loss of an important tumor suppressor activity
(ies) with important implications in endometrial carci-
nogenesis, at least in this tumor model analyzed. Earlier
m o l e c u l a rd a t ac o n f i r m sa n de x t e n d st h i st h e o r y ,a s
recurrent allelic imbalances/loss of heterozygosity in
three independent regions of distal RNO10 have earlier
been reported in BDII rat ECs [49-51].
Conclusions
In conclusion, we found SKY analysis a valuable techni-
que for detailed cytogenetic analysis of experimental
tumors. SKY analysis of 21 experimental ECs developed
in a well-characterized rat tumor model revealed non-
random numerical and structural chromosome changes,
including gain of RNO4, loss of RNO15, and structural
changes in RNO3, RNO6, RNO10, RNO11, RNO12, and
RNO20. The non-random nature of these events, as
documented by their high frequencies of incidence, is
suggestive for dynamic selection for these changes during
BDII EC tumorigenesis and therefore for their potential
contribution into development of this malignancy.
Detailed molecular analysis of the identified genetic
changes in this study and comparative analysis with the
findings in human ECs may provide new insights into
underlying mechanisims in EC tumorigenesis.
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strain; SKY: spectral karyotyping.
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